Jana Skřičková

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

Petr Zatloukal, Luboš Petruželka, Milada Zemanová et al. · Lung Cancer · 2003 · 161 citations

Medicine, Phase Iii, Metronomic Therapy +7

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Petra Zemanová et al. · Anticancer Research · 2020 · 82 citations · Full text

Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases—the role of factors affecting assay performance

Zdeněk Ráčil, Iva Kocmanová, Martina Tošková et al. · International Journal of Infectious Diseases · 2011 · 53 citations · Full text